Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review

被引:66
作者
Corti, C. [1 ,2 ]
Antonarelli, G. [1 ,2 ]
Scotte, F. [3 ,4 ]
Spano, J. P. [5 ]
Barriere, J. [6 ]
Michot, J. M. [7 ]
Andre, F. [8 ]
Curigliano, G. [1 ,2 ]
机构
[1] IRCCS, European Inst Oncol, Div New Drugs & Early Drug Dev Innovat Therapies, Via Ripamonti 435, I-20141 Milan, Italy
[2] Univ Milan, Dept Oncol & Haematol DIPO, Milan, Italy
[3] Gustave Roussy Canc Campus, Villejuif, France
[4] Gustave Roussy, Dept Interdisciplinaire Org Parcours Patients, Villejuif, France
[5] APHP Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ INSERM 1, Paris, France
[6] Clin St Jean, Dept Med Oncol, Cagnes Sur Mer, France
[7] Gustave Roussy Canc Campus, Drug Dev Dept DITEP, Villejuif, France
[8] Univ Paris Saclay, Predict Biomarkers & Novel Therapeut Strategies, Inst Gustave Roussy, Univ Paris Sud,INSERM 981, Villejuif, France
关键词
COVID19; Sars-CoV-2; vaccine; immunogenicity; cancer; seroconversion; IMMUNE-RESPONSES; NEUTRALIZING ANTIBODIES; SARS-COV-2; VACCINATION; SOLID CANCER; HEPATITIS-B; VACCINES; INFECTION; EFFICACY; IMMUNOGENICITY; MALIGNANCIES;
D O I
10.1016/j.annonc.2021.10.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Coronavirus disease 2019 (COVID-19) has affected >210 million people worldwide. An optimal therapeutic approach for COVID-19 remains uncertain, to date. Since the history of cancer was linked to higher mortality rates due to COVID-19, the establishment of a safe and effective vaccine coverage is crucial in these patients. However, patients with cancer (PsC) were mostly excluded from vaccine candidates' clinical trials. This systematic review aims to investigate the current available evidence about the immunogenicity of COVID-19 vaccines in PsC. Patients and methods: All prospective studies that evaluated the safety and efficacy of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were included, with immunogenicity after the first and the second dose as the primary endpoint, when available. Results: Vaccination against COVID-19 for PsC seems overall safe and immunogenic after well-conducted vaccination schedules. Yet the seroconversion rate remains lower, lagged or both compared to the general population. Patients with hematologic malignancies, especially those receiving B-cell-depleting agents in the past 12 months, are the most at risk of poor seroconversion. Conclusion: A tailored approach to vaccination may be proposed to PsC, especially on the basis of the type of malignancy and of the specific oncologic treatments received.
引用
收藏
页码:158 / 168
页数:11
相关论文
共 99 条
[1]   B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny [J].
Anolik, Jennifer H. ;
Friedberg, Jonathan W. ;
Zheng, Bo ;
Barnard, Jennifer ;
Owen, Teresa ;
Cushing, Emily ;
Kelly, Jennifer ;
Milner, Eric C. B. ;
Fisher, Richard I. ;
Sanz, Inaki .
CLINICAL IMMUNOLOGY, 2007, 122 (02) :139-145
[2]   Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel [J].
Bar-On, Yinon M. ;
Goldberg, Yair ;
Mandel, Micha ;
Bodenheimer, Omri ;
Freedman, Laurence ;
Kalkstein, Nir ;
Mizrahi, Barak ;
Alroy-Preis, Sharon ;
Ash, Nachman ;
Milo, Ron ;
Huppert, Amit .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (15) :1393-1400
[3]   Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors [J].
Barriere, J. ;
Chamorey, E. ;
Adjtoutah, Z. ;
Castelnau, O. ;
Mahamat, A. ;
Marco, S. ;
Petit, E. ;
Leysalle, A. ;
Raimondi, V. ;
Carles, M. .
ANNALS OF ONCOLOGY, 2021, 32 (08) :1053-1055
[4]   Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey [J].
Barriere, J. ;
Gal, J. ;
Hoch, B. ;
Cassuto, O. ;
Leysalle, A. ;
Chamorey, E. ;
Borchiellini, D. .
ANNALS OF ONCOLOGY, 2021, 32 (05) :673-674
[5]   Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer [J].
Barriere, Jerome ;
Re, Daniel ;
Peyrade, Frederic ;
Carles, Michel .
EUROPEAN JOURNAL OF CANCER, 2021, 154 :66-72
[6]   Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients [J].
Benda, Magdalena ;
Mutschlechner, Beatrix ;
Ulmer, Hanno ;
Grabher, Claudia ;
Severgnini, Luciano ;
Volgger, Andreas ;
Reimann, Patrick ;
Lang, Theresia ;
Atzl, Michele ;
Huynh, Minh ;
Gasser, Klaus ;
Petrausch, Ulf ;
Fraunberger, Peter ;
Hartmann, Bernd ;
Winder, Thomas .
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (04) :523-531
[7]   Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia [J].
Benjamini, Ohad ;
Rokach, Lior ;
Itchaki, Gilad ;
Braester, Andrei ;
Shvidel, Lev ;
Goldschmidt, Neta ;
Shapira, Shirley ;
Dally, Najib ;
Avigdor, Abraham ;
Rahav, Galia ;
Lustig, Yaniv ;
Ben David, Shirley Shapiro ;
Fineman, Riva ;
Paz, Alona ;
Bairey, Osnat ;
Polliack, Aaron ;
Levy, Ilana ;
Tadmor, Tamar .
HAEMATOLOGICA, 2022, 107 (03) :625-634
[8]   Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses [J].
Benotmane, Ilies ;
Gautier, Gabriela ;
Perrin, Peggy ;
Olagne, Jerome ;
Cognard, Noelle ;
Fafi-Kremer, Samira ;
Caillard, Sophie .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (11) :1063-1065
[9]  
Bilich T, 2021, CANCER DISCOV, V11, P1982, DOI 10.1158/2159-8290.CD-21-0191
[10]   Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias [J].
Branagan, Andrew R. ;
Duffy, Eamon ;
Gan, Geliang ;
Li, Fangyong ;
Foster, Connor ;
Verma, Rakesh ;
Zhang, Lin ;
Parker, Terri L. ;
Seropian, Stuart ;
Cooper, Dennis L. ;
Brandt, Debra ;
Kortmansky, Jeremy ;
Witt, Davit ;
Ferencz, Thomas M. ;
Dhodapkar, Kavita M. ;
Dhodapkar, Madhav, V .
BLOOD ADVANCES, 2021, 5 (05) :1535-1539